Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2506-2516

  Skoura, Athanasia ^a   Sanchez, Teresa ^a   Claffey, Kevin ^a   Mandala, Suzanne M ^b   Proia, Richard L ^c   Hla, Timothy ^a,d  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; G PROTEIN COUPLED RECEPTOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETINA;

ANIMALS; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, LYSOSPHINGOLIPID; RETINAL DISEASES;

EID: 34848892421     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31123     Document Type: Article

References (63)

1. Spiegel, S., and Milstien, S. 2003. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4:397-407.
2. Saba, J.D., and Hla, T. 2004. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ. Res. 94:724-734.
3. Lee, M.J., et al. 1998. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 279:1552-1555.
4. Windh, R.T., et al. 1999. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J. Biol. Chem. 274:27351-27358.
5. Sanchez, T., and Hla, T. 2004. Structural and functional characteristics of S1P receptors. J. Cell. Biochem. 92:913-922.
6. Hla, T. 2004. Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 15:513-520.
7. Chae, S.S., Paik, J.H., Furneaux, H., and Hla, T. 2004. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. 114:1082-1089. doi:10.1172/JCI200422716.
8. LaMontagne, K., et al. 2006. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66:221-231.
9. Sanchez, T., et al. 2003. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278:47281-47290.
10. Sanna, M.G., et al. 2006. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2:434-441.
11. Liu, Y., et al. 2000. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106:951-961.
12. Paik, J.H., et al. 2004. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev. 18:2392-2403.
13. Kono, M., et al. 2004. The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J. Biol. Chem. 279:29367-29373.
14. Kono, M., et al. 2007. Deafness and stria vascularis defects in S1P2 receptor null mice. J. Biol. Chem. 282:10690-10696.
15. Herr, D.R., et al. 2007. Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J. Neurosci. 27:1474-1478.
16. Kupperman, E., An, S., Osborne, N., Waldron, S., and Stainier, D.Y. 2000. A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. Nature. 406:192-195.
17. Connolly, S.E., Hores, T.A., Smith, L.E., and D'Amore, P.A. 1988. Characterization of vascular development in the mouse retina. Microvasc. Res. 36:275-290.
18. Gariano, R.F., and Gardner, T.W. 2005. Retinal angiogenesis in development and disease. Nature. 438:960-966.
19. Saint-Geniez, M., and D'Amore, P.A. 2004. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int. J. Dev. Biol. 48:1045-1058.
20. Smith, L.E., et al. 1994. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35:101-111.
21. Pierce, E.A., Avery, R.L., Foley, E.D., Aiello, L.P., and Smith, L.E. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 92:905-909.
22. Hackett, S.F., et al. 2000. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J. Cell. Physiol. 184:275-284.
23. Gerhardt, H., et al. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161:1163-1177.
24. Chan-Ling, T., et al. 2004. Desmin ensheathment ratio as an indicator of vessel stability: evidence in normal development and in retinopathy of prematurity. Am. J. Pathol. 165:1301-1313.
25. Uemura, A., Kusuhara, S., Wiegand, S.J., Yu, R.T., and Nishikawa, S. 2006. Tlx acts as a proangiogenic switch by regulating extracellular assembly of fibronectin matrices in retinal astrocytes. J. Clin. Invest. 116:369-377. doi:10.1172/JCI25964.
26. Shih, S.C., Ju, M., Liu, N., and Smith, L.E. 2003. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J. Clin. Invest. 112:50-57. doi:10.1172/ JCI200317808.
27. Aiello, L.P., et al. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U. S. A. 92:10457-10461.
28. Hackett, S.F., Wiegand, S., Yancopoulos, G., and Campochiaro, P.A. 2002. Angiopoietin-2 plays an important role in retinal angiogenesis. J. Cell. Physiol. 192:182-187.
29. Sennlaub, F., Courtois, Y., and Goureau, O. 2001. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J. Clin. Invest. 107:717-725.
30. Ishida, S., et al. 2003. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198:483-489.
31. Ritter, M.R., et al. 2006. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J. Clin. Invest. 116:3266-3276. doi:10.1172/JCI29683.
32. Thurston, G., Baluk, P., Hirata, A., and McDonald, D.M. 1996. Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am. J. Physiol. 271:H2547-H2562.
33. Sennlaub, F., et al. 2003. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 108:198-204.
34. Inoue, H., Umesono, K., Nishimori, T., Hirata, Y., and Tanabe, T. 1999. Glucocorticoid-mediated suppression of the promoter activity of the cyclooxygenase-2 gene is modulated by expression of its receptor in vascular endothelial cells. Biochem. Biophys. Res. Commun. 254:292-298.
35. Yu, J., et al. 2005. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc. Natl. Acad. Sci. U. S. A. 102:10999-11004.
36. Dudzinski, D.M., Igarashi, J., Greif, D., and Michel, T. 2006. The regulation and pharmacology of endothelial nitric oxide synthase. Annu. Rev. Pharmacol. Toxicol. 46:235-276.
37. Hofmann, J.J., and Luisa Iruela-Arispe, M. 2007. Notch expression patterns in the retina: an eye on receptor-ligand distribution during angiogenesis. Gene Expr. Patterns. 7:461-470.
38. Fox, T.E., et al. 2006. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes. 55:3573-3580.
39. Acharya, U., et al. 2003. Modulating sphingolipid biosynthetic pathway rescues photoreceptor degeneration. Science. 299:1740-1743.
40. Maines, L.W., French, K.J., Wolpert, E.B., Antonetti, D.A., and Smith, C.D. 2006. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest. Ophthalmol. Vis. Sci. 47:5022-5031.
41. Min, J.K., Yoo, H.S., Lee, E.Y., Lee, W.J., and Lee, Y.M. 2002. Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase. Anal. Biochem. 303:167-175.
42. Venkataraman, K., et al. 2006. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem. J. 397:461-471.
43. Hellstrom, M., et al. 2007. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 445:776-780.
44. Sanchez, T., et al. 2007. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler. Thromb. Vasc. Biol. 27:1312-1318.
45. Otani, A., et al. 2002. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat. Med. 8:1004-1010.
46. Kaur, C., Sivakumar, V., and Foulds, W.S. 2006. Early response of neurons and glial cells to hypoxia in the retina. Invest. Ophthalmol. Vis. Sci. 47:1126-1141.
47. Hernandez, G.L., et al. 2001. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 193:607-620.
48. Tsujii, M., et al. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells [erratum, 1998, 94:following 271]. Cell. 93:705-716.
49. Wilkinson-Berka, J.L., Alousis, N.S., Kelly, D.J., and Gilbert, R.E. 2003. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 44:974-979.
50. Leahy, K.M., et al. 2002. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:625-631.
51. Liu, X.H., et al. 2002. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 277:50081-50086.
52. Jones, M.K., et al. 1999. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5:1418-1423.
53. Chang, S.H., et al. 2004. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 101:591-596.
54. Sasaki, K., et al. 2006. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc. Natl. Acad. Sci. U. S. A. 103:14537-14541.
55. Limbourg, F.P., et al. 2002. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids [erratum 2003, 111:759]. J. Clin. Invest. 110:1729-1738. doi:10.1172/JCI200215481.
56. Brooks, S.E., et al. 2001. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest. Ophthalmol. Vis. Sci. 42:222-228.
57. Eto, M., et al. 2001. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ. Res. 89:583-590.
58. Hernandez-Perera, O., et al. 1998. Effects of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101:2711-2719.
59. Liao, J.K., et al. 1995. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J. Clin. Invest. 96:2661-2666.
60. Sanchez, T., et al. 2005. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc. Natl. Acad. Sci. U. S. A. 102:4312-4317.
61. Takemoto, M., Sun, J., Hiroki, J., Shimokawa, H., and Liao, J.K. 2002. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 106:57-62.
62. Singer, I.I., et al. 2005. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J. Immunol. 175:7151-7161.
63. Forrest, M., et al. 2004. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. 309:758-768.